Phase I Trial of Cetuximab and Erlotinib (EGFR Inhibitors) and SIR-Spheres (Yttrium Microspheres) in Patients With Advanced Malignancies and Liver Metastases

Trial Profile

Phase I Trial of Cetuximab and Erlotinib (EGFR Inhibitors) and SIR-Spheres (Yttrium Microspheres) in Patients With Advanced Malignancies and Liver Metastases

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 08 Apr 2013

At a glance

  • Drugs Cetuximab (Primary) ; Erlotinib (Primary) ; Yttrium-90
  • Indications Cancer metastases; Liver cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Oct 2012 Planned number of patients changed from 68 to 136 as reported by ClinicalTrials.gov.
    • 24 Oct 2012 Planned End Date changed from 1 Sep 2019 to 1 Dec 2019 as reported by ClinicalTrials.gov.
    • 24 Oct 2012 Planned initiation date changed from 1 Sep 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top